6 July 2020
Oxford University’s LIFE project has launched a new set of app-based training scenarios that help healthcare workers in Africa safely manage and treat cases of children with suspected COVID-19
3 July 2020
Dr Le Van Tan in OUCRU, in collaboration with the Hospital for Tropical Diseases and the Department of Health, has shown that it is common for people who are infected with the virus that causes COVID-19 (SARS-CoV-2) to have no symptoms whatsoever. By testing quarantined people in Vietnam, his team was able to detect asymptomatic individuals. The virus disappeared faster from the bodies of the asymptomatic carriers than from that of symptomatic individuals, but it appeared that some of them still managed to pass the infection on to others.
3 July 2020
The European Commission has granted Marketing Authorisation to Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford. The Ebola vaccine has already been deployed in the North Kivu region of the Democratic Republic of the Congo (DRC), following recommendation from the WHO’s Strategic Advisory Group of Experts (SAGE), and in Rwanda – following conditional approval in 2019 under an ‘exceptional emergency’ – as part of outbreak containment efforts in the region.
No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY
29 June 2020
The RECOVERY trial was established in March as a randomised clinical trial to test a range of potential treatments for COVID-19, including lopinavir-ritonavir, an antiviral treatment commonly used to treat HIV. There was no significant difference in the primary endpoint of 28-day mortality, and the results were consistent in different subgroups of patients. There was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay. The trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed that treatment arm.
UK regulator gives green light to clinical trial of hydroxychloroquine to prevent Covid-19 in healthcare workers
29 June 2020
The UK regulator MHRA announced on 26 June that it would again permit recruitment to the COPCOV COVID-19 prevention clinical trial. The MHRA decision came 5 weeks after it reacted immediately to the now-discredited paper published in The Lancet suggesting harms with hydroxychloroquine, and paused recruitment of UK participants. But The Lancet paper was based on fabricated data and was swiftly retracted. After this interruption, recruitment around the globe to COPCOV can now resume.
Dexamethasone reduces death in hospitalised patients with severe respiratory complications of COVID-19
16 June 2020
The RECOVERY trial tests a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment). Patients were randomised to receive dexamethasone 6 mg once per day for ten days and were compared with patients receiving usual care alone. Dexamethasone reduced deaths by one-third in ventilated patients and by one-fifth in other patients receiving oxygen only; there was no benefit among those patients who did not require respiratory support. Based on these results, 1 death would be prevented by treatment of around 8 ventilated patients or around 25 patients requiring oxygen alone.
5 June 2020
A new statement has been released from Professor Peter Horby and Professor Martin Landray, Chief Investigators of the RECOVERY Trial. RECOVERY was established in March as a randomised clinical trial to test a range of potential drugs for COVID-19, including hydroxycholoroquine. The trial has proceeded at unprecedented speed, enrolling over 11,000 patients from 175 NHS hospitals in the UK. The chief investigators have concluded that there is no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19.
Global clinical trial of 40,000+ healthcare workers begins to test in UK if chloroquine and hydroxychloroquine can prevent COVID-19
21 May 2020
A global study to test if either chloroquine or hydroxychloroquine can prevent COVID-19 in vital frontline healthcare workers will open to UK participants at hospital sites in Brighton and Oxford today.
20 May 2020
The COVID-19 pandemic has seen some extraordinary medical feats and achievements, which are being rightly celebrated. Researchers at Oxford University have been at the forefront of global efforts, including the first human trials of a COVID-19 vaccine, and the world’s biggest trial of potential COVID-19 treatments, RECOVERY.
12 May 2020
The COVID-19 International Modelling Consortium (CoMo Consortium) was created by researchers at the University of Oxford and Cornell University, is partnering with infectious disease modellers and public health experts from over 40 countries in Africa, Asia and America. The CoMo Consortium uses a participatory approach to provide decision-making support to policymakers, using evidence from epidemiological and economic models adapted to each country’s context.
5 May 2020
The Global Health Network and the Family Larsson Rosenquist Foundation (FLRF) launch LactaHub: an open access knowledge platform featuring scientific and evidence-based information on breastfeeding and breastmilk for health professionals
1 May 2020
The SEBCOV study aims to produce evidence to inform public health measures such as communications, quarantine, self-isolation, social distancing and travel restrictions for the COVID-19 pandemic. This study is run in four countries: UK, Thailand, Italy and Malaysia.
30 April 2020
The results of a placebo-controlled randomised trial of remdesivir in COVID-19 patients have been published in the Lancet. Supported by the ISARIC Support Centre, scientists in China launched a trial of remdesivir in patients hospitalised with COVID-19. The results found no clinical benefit from use of the drug; however, while not statistically significant, the time to clinical improvement and duration of invasive mechanical ventilation were shorter in people treated with remdesivir.
29 April 2020
The Epidemiology Department of MORU and National Malaria Control Programme, Cambodia (CNM) have begun to implement a study to assess the efficacy of prophylaxis with artemether-lumefantrine (PAL) against forest malaria in Siem Pang District, north-eastern Cambodia bordering Laos.
27 April 2020
The International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) is producing a weekly report using clinical data from its COVID-19 database. To date, this includes data from 19,809 individuals from 244 sites across 25 countries.
24 April 2020
A site team in Malawi used the WWARN Malaria Clinical Trials Toolkit for their antimalarial-antiretroviral drug-drug interaction trial with pregnant women. Clifford Banda and his staff used the CDISC-compliant WWARN REDCap data base template as the basis for their data collection and capture, and used or adapted the many WWARN standard operating procedures and their forms for various administrative, clinical, investigational product, quality, data management and safety aspects of their planned work.
23 April 2020
Less than a month after it was announced, the MORU-led COPCOV study has made quick progress and expects to begin enrolling participants by the end of April.
17 April 2020
The UK government is funding 21 new novel coronavirus research studies, including a project led by Professor Trudie Lang. Research must be undertaken everywhere across the globe during this pandemic. Access and ability to undertake research should be equitable, and this research project, working through The Global Health Network, aims to support healthcare teams in low-resource settings. This is a University of Oxford led programme aiming to enable more and better research in diseases, communities and settings where evidence is lacking.
The RECOVERY Trial, which is testing potential treatments for COVID19, has recruited 1000 patients in 15 days
6 April 2020
The world’s largest randomised clinical trial of potential coronavirus treatments is well underway in the UK as part of the race to find a treatment. A number of promising treatments are being tested and, if the science supports it, will be given to NHS patients as quickly as possible. Definitive results on whether the treatments are safe and effective are expected within months and, if positive, they could potentially benefit hundreds of thousands of people worldwide. Almost 1,000 patients from 132 different hospitals have been recruited in just 15 days and thousands more are expected to join the Randomised Evaluation of COV-id19 thERapY (RECOVERY) trial in the coming weeks, making it the largest randomised controlled trial of potential COVID-19 treatments in the world.
30 March 2020
Researchers at MORU and two institutions in the US (University of Washington and La Jolla Institute for Immunology) receive grants from the COVID-19 Therapeutics Accelerator, a large-scale initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to speed the development of and access to therapies for COVID-19.
30 March 2020
The problem of substandard and falsified (SF) medical products affects all countries but few regulatory authorities or pharmaceutical companies have policies of publicly releasing data. As a first step in tracking this global issue, IDDO’s Medicine Quality Research Group, with the MORU Tropical Health Network and supported by a grant from the Wellcome Trust, has today launched a new, free-to-use, online tool, the Medicine Quality Monitoring Globe, (MQM Globe) which maps SF news reports worldwide in real time.
23 March 2020
Oxford Nuffield Department of Population Health started a new trial of potential treatments for adults patients hospitalised with confirmed COVID-19 with the collaboration of Professor Peter Horby
20 March 2020
Researchers from across the Medical Sciences Division are working hard to combat the COVID-19 crises. With particular strengths in infectious diseases and international health, we are well placed to contribute to better understanding and effectively controlling the epidemic. Many of these researchers are affiliated with the Centre for Tropical Medicine and Global Health
13 March 2020
NDM is prioritising collaborative projects for front line actions to support global efforts in tackling nCoV. ISARIC has launched a number of international resources available free of charge, through which investigators retain full control of data and samples. Gavin Screaton and Guy Thwaites are looking at neutralising antibody responses. Other NDM researchers work on vaccine development, structure, protective immune response, UK hospital settings and pathogens evolution.
11 March 2020
Adding a third anti-malaria drug to current artemisinin-combination therapies (ACTs) provides effective treatment against multidrug-resistant falciparum malaria in Southeast Asia, say Oxford researchers in a study in The Lancet. Using TACTs should extend current malaria drugs so drug-resistant malaria doesn't kill millions more and derail hopes of controlling and eliminating malaria.
4 March 2020
From April 2020, an existing successful Health Protection Research Unit will be bolstered by the addition of collaborators from the University of Oxford. Funded by NHIR, the next phase of the HPRU in Emerging and Zoonotic Infections will build on the work already done by the University of Liverpool, the Liverpool School of Tropical Medicine, and Public Health England.
28 February 2020
A statistical analysis of WWARN data from 4,214 participants across multiple study sites in Africa has been published in BMC Medicine. Results indicate that the local prevalence of resistance-associated markers should be considered when choosing a first-line drug to ensure optimal duration of protection.
13 February 2020
What do a mathematician, an epidemiologist, a vaccine developer, a protein crystallographer and a whole bevy of immunologists and infectious disease specialists have in common? Answer: they’re just some of the Oxford University researchers coming together to fight the novel Coronavirus outbreak. Science blog by Charvy Narain
International research consortium activates clinical study for novel coronavirus in England and Scotland
31 January 2020
In response the novel coronavirus emergency, the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) has activated its Clinical Characterisation Protocol (CCP) for emerging infections in England and Scotland.
30 January 2020
Policy makers are interested in practical steps to a more gender-equitable and transformative health system. A guide published by Research in Gender & Ethics aims to help policy makers adopt a gender lens in policy deliberations on health systems. In order to prompt reflections on how gender affects health systems, we include case studies from Cambodia, Democratic Republic of Congo, Kenya, Liberia, Malawi, Sierra Leone, South Africa, Tanzania and Uganda.
28 January 2020
Governments, funders, and research bodies must take action to ensure that research is undertaken ethically during global health emergencies, says a new report from the Nuffield Council on Bioethics.
28 January 2020
This pop-up space for 2019 Novel Coronavirus (2019-nCoV) supports evidence generation by pooling protocols, tools, guidance, templates, and research standards generated by researchers and networks working on the response to this outbreak. Findings from previous outbreaks, largely obtained during MERS and SARS outbreaks, are also available. We aim to make research faster and easier, and to enable standardised, quality data to be collected and prepared for sharing.
22 January 2020
The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) is adapting its existing tools, designed for emerging respiratory pathogens, for the current outbreak of global significance. This is an international resource for facilitating the collection of standardised clinical data on patients hospitalised with suspected or confirmed infection with novel coronavirus.
17 January 2020
A specialist technique used to study drugs has been completed for the first time during an outbreak of Ebola virus disease.
Global study highlights the extent and impact of drug-resistant enteric fever and the urgent need for new approaches
23 December 2019
A new study conducted by Christiane Dolecek and colleagues analysed data on antimicrobial resistance of the bacteria Salmonella Typhi and Salmonella Paratyphi, from around the globe, spanning the time from 1990 to 2018. The study highlights the impact of drug resistance and the urgent need for interventions.
18 December 2019
Science Blog - George Busby of Oxford University's Big Data Institute discusses his team's research into human genetic resistance to malaria and humanity's age-old struggle against the disease.
11 December 2019
A large field study of typhoid conjugate vaccine (TCV) in Nepal has shown a single dose to be safe and effective in reducing typhoid in children aged 9 months to <16 years in an endemic setting. OUCRU-Nepal Professor Buddha Basnyat took part in this study.
14 November 2019
Life-saving Instruction for Emergences (LIFE), a virtual reality (VR) medical training platform developed by doctors, nurses and researchers at the KEMRI-Wellcome Trust Research Programme (KWTRP) in Kenya and Oxford University with support from HTC, has officially launched today. This new virtual reality medical training app uses HTC VIVE Focus Plus for training doctors and nurses to save lives.
New research supports co-administration of primaquine with artemisinin-based combination therapies for P. vivax malaria
8 October 2019
An individual patient data meta-analysis of 2,017 patients from 19 studies has found a high risk of recurrence following treatment of P. vivax malaria with artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) unless they are co-administered with primaquine. The research supports recommendations that these artemisinin-based combination therapies (ACT) should be combined with primaquine.
4 October 2019
The Oxford based OHSCAR team is delighted to be a partner the NEST360 project working with KEMRI-Wellcome and the Kenya Paediatric Research Consortium in Kenya to support this effort to improve care care of the sick newborn and save lives
18 September 2019
This report presents research on the current state of governance and coordination of health emergency preparedness and response. It highlights key challenges to address for the future. The report was commissioned by the Global Preparedness Monitoring Board to inform their inaugural report launched on 18th September 2019.
18 September 2019
In partnership with the Wellcome Innovations Flagship Programme, MORU launched its Critical Care Asia Network project with its first investigators’ meeting on 19-20 Aug in Bangkok. The project will establish an Asian ICU network across 42 ICUs in nine countries and implement a setting-adapted electronic registry.
13 September 2019
In Kenya, the poorest of the poor carry the highest burden of disease. From locally-made, low-cost herbal remedies to affordable hard floors for households, researchers and communities are developing new ways to deal with jiggers in Kenya. Lynne Elson, a research fellow at KEMRI Wellcome Trust, lead a study to determine whether neem and coconut oil reduce inflammation, pain and itching better than the standard treatment in seven days.
8 September 2019
Human trials of new antimalarial drugs are in the pipeline after KEMRI scientists successfully used bacteria to kill the parasite that causes the disease. Trials in Burkina Faso showed that Ivermectin, a conventional drug used for parasitic diseases including river blindness and elephantiasis, reduced transmission rates. The medication worked by making the blood of people who were repeatedly vaccinated lethal to mosquitoes. The study also found that Ivermectin can kill plasmodium falciparum, the malaria parasite carried by female mosquitoes, when administered to humans.
26 August 2019
The provision of high-quality care to sick newborns presents challenges in any health system. International guidelines suggest that even for babies who do not require intensive care, there should be one nurse for every 2 – 4 sick babies. However, recent studies conducted in Nairobi show that one nurse takes care of between 20 – 40 newborns. In a recently published policy brief the KEMRI Wellcome Trust programme highlights the experience of nurses in Nairobi’s New Born Units.
6 August 2019
IDDO has launched a new global Chagas scientific collaboration with the Drugs for Neglected Diseases initiative (DNDi). The new platform will collate and standardise data to accelerate better treatments for the 6–7 million people worldwide with Chagas disease.
1 August 2019
The Nairobi Programme at KEMRI Wellcome Trust Research Programme hosts over 17 principal researchers, 15 PhD fellows and a dedicated team of over 40 research assistants spanning clinical research, health services research, population health research, and health systems and economics research. Learn more about the ongoing research and the principal researchers behind the work.
Latest research finds primaquine improves haemoglobin by day 42 following treatment of P. vivax malaria
1 August 2019
An IDDO/WWARN study has found that primaquine is not associated with increased levels of anaemia following treatment of patients without G6PD deficiency for P. vivax malaria and should be used as part of a radical cure. In the largest study of its kind to date, researchers carried out a systematic review and individual patient data meta-analysis which involved 3,421 patients in 29 studies published in BMC Medicine.
Better Research for Better Health: University of Oxford and Fiocruz partner to improve health research and capacity development globally
31 July 2019
A new strategic partnership between Fiocruz and The Global Health Network will amplify the impact of Fiocruz’s health research and capacity development initiatives by promoting research capacity building across Portuguese-speaking countries, and enabling research findings from the Zika outbreak to benefit public health worldwide.
25 July 2019
KWTRP has launched a dataset of comprehensive public health facilities from 50 countries in sub- Saharan Africa. This new dataset locates health facilities in relation to the communities they are intended to serve, to help ensure that services are accessible to the right populations and that no one is geographically marginalized from essential services. This is critical for attainment of Sustainable Development Goal 3 on good health and wellbeing.